Climb Bio Inc
CLYM4.729USD
-0.171-3.49%
交易中 （美東）報價延遲15分鐘
322.44M總市值
虧損本益比TTM
關於 Climb Bio Inc 公司
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc簡介
公司代碼CLYM
公司名稱Climb Bio Inc
上市日期Aug 10, 2021
CEOBrennan (Aoife M)
員工數量17
證券類型Ordinary Share
年結日Aug 10
公司地址20 William Street
城市WELLESLEY HILLS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02481
電話18668572596
網址https://climbbio.com/
公司代碼CLYM
上市日期Aug 10, 2021
CEOBrennan (Aoife M)
Climb Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
26.26%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.93%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
其他
60.76%
持股股東
持股股東
佔比
RA Capital Management, LP
26.26%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.93%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
其他
60.76%
股東類型
持股股東
佔比
Venture Capital
33.94%
Hedge Fund
9.63%
Investment Advisor
8.07%
Investment Advisor/Hedge Fund
1.20%
Individual Investor
0.81%
Research Firm
0.80%
其他
45.56%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
180
50.12M
94.21%
+7.08K
2025Q3
182
50.11M
95.00%
-5.30M
2025Q2
174
55.41M
95.70%
-2.05M
2025Q1
161
57.46M
90.60%
-8.97M
2024Q4
149
56.10M
86.82%
+979.54K
2024Q3
120
56.83M
81.50%
+4.66M
2024Q2
84
51.93M
31.41%
+31.40M
2024Q1
82
18.86M
80.37%
-3.42M
2023Q4
86
18.86M
80.98%
+125.11K
2023Q3
87
18.73M
82.50%
-1.84K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
31.42M
46.37%
--
--
Jun 30, 2025
Pontifax Venture Capital
5.21M
7.68%
+5.21M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.33M
1.96%
-171.31K
-11.40%
Jun 30, 2025
Affinity Asset Advisors LLC
1.50M
2.21%
--
--
Jun 30, 2025
Kynam Capital Management LP
1.03M
1.52%
-18.66K
-1.78%
Jun 30, 2025
Tang Capital Management, LLC
1.00M
1.48%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
829.63K
1.22%
-1.27M
-60.45%
Jun 30, 2025
Peapod Lane Capital LLC
555.67K
0.82%
+1.85K
+0.33%
Jun 30, 2025
Cantor Fitzgerald, L.P
2.50M
3.69%
+503.12K
+25.16%
Jun 30, 2025
Renaissance Technologies LLC
495.50K
0.73%
-18.90K
-3.67%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Climb Bio Inc的前五大股東是誰？
Climb Bio Inc的前五大股東如下：
RA Capital Management, LP持有股份：31.42M佔總股份比例：46.37%。
Pontifax Venture Capital持有股份：5.21M佔總股份比例：7.68%。
The Vanguard Group, Inc.持有股份：1.33M佔總股份比例：1.96%。
Affinity Asset Advisors LLC持有股份：1.50M佔總股份比例：2.21%。
Kynam Capital Management LP持有股份：1.03M佔總股份比例：1.52%。
RA Capital Management, LP持有股份：31.42M佔總股份比例：46.37%。
Pontifax Venture Capital持有股份：5.21M佔總股份比例：7.68%。
The Vanguard Group, Inc.持有股份：1.33M佔總股份比例：1.96%。
Affinity Asset Advisors LLC持有股份：1.50M佔總股份比例：2.21%。
Kynam Capital Management LP持有股份：1.03M佔總股份比例：1.52%。
Climb Bio Inc的前三大股東類型是什麼？
Climb Bio Inc 的前三大股東類型分別是：
RA Capital Management, LP
Pontifax Venture Capital
The Vanguard Group, Inc.
RA Capital Management, LP
Pontifax Venture Capital
The Vanguard Group, Inc.
有多少機構持有Climb Bio Inc(CLYM)的股份？
截至2025Q4，共有180家機構持有Climb Bio Inc的股份，合計持有的股份價值約為50.12M，占公司總股份的94.21% 。與2025Q3相比，機構持股有所增加，增幅為-0.80%。
哪個業務部門對Climb Bio Inc的收入貢獻最大？
在--，--業務部門對Climb Bio Inc的收入貢獻最大，創收--，占總收入的--% 。
